Results 291 to 300 of about 3,900,516 (357)
A Look to the Future: Potential Theranostic Applications in Head and Neck Tumors. [PDF]
Oldan JD, Solnes LB, Chin BB, Rowe SP.
europepmc +1 more source
Noise‐induced synaptopathy (NIS) is largely reversible due to self‐repair. NIS and noise‐induced hidden hearing loss are two concepts with similarities and differences. The major hearing deficits in NIHHL are temporal processing disorders. The translation of animal data in NIS studies to humans is hindered by many factors.
Hui Wang, Steven J Aiken, Jian Wang
wiley +1 more source
Vitamin D and Clinical Outcomes in Head and Neck Cancer: A Systematic Review. [PDF]
Mot CI+8 more
europepmc +1 more source
This study shows that gene replacement therapy using the AAV2/Anc80L65 virus can successfully restore hearing and balance in Ush1c knockout mice. The treatment leads to lasting improvements in both auditory and vestibular functions, highlighting its potential as a therapeutic approach for genetic hearing loss and vestibular disorders in humans ...
Weinan Du+13 more
wiley +1 more source
Liquid Biopsy in HPV-Associated Head and Neck Cancer: A Comprehensive Review. [PDF]
Parisi FM+10 more
europepmc +1 more source
Large‐Scale Plasma Proteomics to Profile Pathways and Prognosis of Chronic Pain
This study delineates both common and site‐specific proteins linked to various chronic pain conditions, elucidating their implications across molecular pathways and health status. These findings, particularly those proteins with genetic causal links to pain or predictive capabilities, have the potential to significantly benefit both research and ...
Ze‐Yu Li+17 more
wiley +1 more source
Dual-energy CT in head and neck applications.
Tunlayadechanont P, Sananmuang T.
europepmc +1 more source
Impact of the COVID-19 Pandemic on the Treatment of Head and Neck Cancers. [PDF]
Lee ML, Finegersh A, Chen MM.
europepmc +1 more source
Antigen‐Targeting Inserted Nanomicelles Guide Pre‐Existing Immunity to Kill Head and Neck Cancer
This study introduces a tumor‐targeted nanomicelle platform (preS1‐pHLIP) that exploits pre‐existing antiviral immunity to combat heterogeneous cancers. By delivering viral antigens to label tumors as virus‐like targets, the nanomicelles activate antiviral B and T cells, triggering in situ tumor lysis.
Lizhuo Zhang+16 more
wiley +1 more source
The microRNA-6510 as a potential tumor suppressor in head and neck cancer. [PDF]
Sobecka-Giel A+5 more
europepmc +1 more source